WHO ICTRP trial
CloseHER2 Home: a community pharmacy-led pathway for the administration of…
ISRCTN15965214 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN15965214 |
|---|---|
| Public title | CloseHER2 Home: a community pharmacy-led pathway for the administration of trastuzumab for HER2-positive breast cancer patients |
| Scientific title | CloseHER2 Home: A feasibility study of a community pharmacy-led pathway for the administration of subcutaneous trastuzumab for HER2-positive breast cancer patients. |
| Primary sponsor | University of Dundee |
| Secondary sponsors | NHS Tayside |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase IV |
| Countries | United Kingdom;Scotland |
| Conditions | HER2-positive breast cancer Cancer |
| Interventions | The intervention under study is a new model of care for the administration of subcutaneous trastuzumab via a community pharmacy-led pathway (CPP). Patients prescribed a course of subcutaneous trastuzumab can elect to have four of their… |
| Registration date | Sep 6, 2022 |
| Target size | 50 |
| Secondary IDs | Nil known;Nil known;2019ON14, IRAS 269056, CPMS 46865 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: